FMR1 and fragile X syndrome: This report highlighted the improvement of the clinical utility of FMR1-carrier screening; by reducing the need of prenatal diagnosis and/or PGT-M for FXS, genetic-counseling resources can be focused on supporting those with a PM with a higher risk of having children with the full mutation [143].